With an Eye on Future Array Development, Invitrogen Licenses Affymetrix s Patents | GenomeWeb

Invitrogen has obtained a non-exclusive, worldwide license to a number of Affymetrix's micorarray patents, the firms announced this week.

Invitrogen is being tight-lipped about which patents it has licensed from Affymetrix and whether it intends to expand into the field of DNA microarrays, but it is clear the firm intends to expand its franchise in the non-coding RNA tools market.

"This was an opportunity for us to bring in some capabilities through additional intellectual property," said Greg Geissman, an Invitrogen spokesman.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.